Evaluation of the NucliSens EasyQ v2.0 assay in comparison with the Roche Amplicor v1.5 and the Roche CAP/CTM HIV-1 Test v2.0 in quantification of C-clade HIV-1 in plasma

Human immunodeficiency virus type 1 (HIV-1) genetic diversity poses a challenge to reliable viral load monitoring. Discrepancies between different testing platforms have been observed, especially for non-clade-B virus. Therefore we compare, in antiretroviral therapy (ART)-naïve South African subject...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2014-08, Vol.9 (8), p.e103983-e103983
Main Authors: Muenchhoff, Maximilian, Madurai, Savathee, Hempenstall, Allison Jo, Adland, Emily, Carlqvist, Anna, Moonsamy, Angeline, Jaggernath, Manjeetha, Mlotshwa, Busisiwe, Siboto, Emma, Ndung'u, Thumbi, Goulder, Philip Jeremy Renshaw
Format: Article
Language:English
Subjects:
Adult
Analysis
Anti-Retroviral Agents - therapeutic use
Antiretroviral agents
Antiretroviral drugs
Antiretroviral therapy
Assaying
Cohort Studies
Correlation analysis
Female
Genetic diversity
Genotype
Highly active antiretroviral therapy
HIV
HIV Infections - blood
HIV Infections - diagnosis
HIV Infections - drug therapy
HIV tests
HIV-1 - genetics
HIV-1 - isolation & purification
HIV-1 - physiology
Human immunodeficiency virus
Humans
Infections
Laboratories
Medicine and health sciences
Pathogenesis
Sensitivity and Specificity
Studies
Viral Load - methods
Viremia
Virus diseases
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Human immunodeficiency virus type 1 (HIV-1) genetic diversity poses a challenge to reliable viral load monitoring. Discrepancies between different testing platforms have been observed, especially for non-clade-B virus. Therefore we compare, in antiretroviral therapy (ART)-naïve South African subjects predominantly infected with HIV-1 clade-C, three commercially available assays: the COBAS AmpliPrep/COBAS TaqMan HIV-1 Test version 2.0 by Roche (CAP/CTM v2.0), the BioMérieux NucliSens Version 2.0 Easy Q/Easy Mag (NucliSens v2.0) and the Roche COBAS Amplicor HIV-1 Monitor Test Version 1.5 (Amplicor v1.5). Strong linear correlation was observed and Bland-Altman analyses showed overall good agreement between the assays with mean viral load differences of 0.078 log cp/ml (NucliSens v2.0 - Amplicor v1.5), 0.260 log cp/ml (CAP/CTM v2.0 - Amplicor v1.5) and 0.164 log cp/ml (CAP/CTM v2.0 - NucliSens v2.0), indicating lower mean viral load results for the Amplicor v1.5 and higher mean readings for the CAP/CTM v2.0. Consistent with observations following previous comparisons of CAP/CTM v2.0 versus Amplicor v1.5, the CAP/CTM v2.0 assay detected low-level viremia (median 65 cp/ml) in more than one-third of those in whom viremia had been undetectable (
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0103983